← All news

ENPICOM announces IGX 2.0

ENPICOM, an innovative bioinformatics software engineering company, announced a major release of its ImmunoGenomiX (IGX) Platform. The platform is designed to streamline the analysis and management of vast amounts of repertoire sequencing data, accelerating the discovery and development of new biological targets. The new software release accelerates and improves the development of novel immunotherapies and vaccines.

Increased demand for new vaccines and precision medicine, as well as shrinking time-to-market expectations, are contributing to a fundamental shift in how new drugs are developed. To fulfill today’s demand for personalized immunotherapies and accessible vaccines, especially against emerging threats like COVID-19, Life Scientists must have efficient data management and analysis tools that allow them to gain more insight into the adaptive immune system.

Immune repertoire sequencing provides an in-depth view of the adaptive immune system and is the most informative way to analyze it. However, repertoire sequencing experiments typically generate millions of sequencing reads per sample, and the amount of publicly available data is growing exponentially. To help researchers effectively manage and make sense out of all this available data, ENPICOM has developed a scalable, versatile tool – the IGX Platform.

Released in April 2019, the IGX Platform is the only end-to-end solution on the market for efficient management, analysis, and visualization of T and B cell receptor sequencing data. With powerful data handling features, an intuitive user interface, and several analysis apps, it helps scientists in academic research centers and biopharmaceutical companies accurately interpret large-scale repertoire data, reduce the time needed to extract biologically and clinically relevant insights, and most importantly, unlock insights that would otherwise have stayed hidden.

With the release of version 2.0, the IGX Platform now supports not only bulk but also single-cell sequencing data, allowing users the complementary benefit of paired chain information. The ability to manage and analyze data from bulk and single-cell workflows in one environment provides unprecedented opportunities for immunomics research and drug development. ENPICOM’s IGX Platform streamlines the analysis process, effectively minimizing data integration difficulties and maximizing scientific output.

Dr. Nicola Bonzanni, CSO at ENPICOM, explains: “The functionalities added to our platform in this new release are based on extensive product discovery interviews among our customers and prospects. I’m very proud that we managed to develop this version according to the planned timeline am and excited to put it in the hands of our customers now.